Ordering
Available Variants5 g
CHA.63176-5g
Price
€125.60
Available – Dispatch in 14 days
25 g
CHA.63176-25g
Price
€474.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 g | CHA.63176-5g | €125.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 g | CHA.63176-25g | €474.40 |
≥98% (TLC), powder, D2 dopamine receptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C17H19ClN2S · HCl |
|---|---|
| CAS Number | 69-09-0 |
| Molecular Weight | 355.33 |
| NACRES | NA.77 |
| PubChem Substance ID | 57654045 |
| UNSPSC Code | 12352200 |
| EC Number | 200-701-3 |
| MDL number | MFCD00012654 |
| Beilstein/REAXYS Number | 3779989 |
| Assay | ≥98% (TLC) |
| Form | powder |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H301,H330 |
| pcodes | P260 - P264 - P270 - P271 - P284 - P304 + P340 + P310 |
| Hazard Classifications | Acute Tox. 1 Inhalation - Acute Tox. 3 Oral |
| Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
Chlorpromazine hydrochloride, with a CAS number of 69-09-0, is a phenothiazine derivative that exhibits a range of pharmacological properties, primarily acting as a dopamine antagonist with antipsychotic and antiemetic effects. It is commonly utilized in the management of schizophrenia, acute psychosis, and severe nausea and vomiting. The compounds mechanism of action involves blocking dopamine receptors in the brain, which helps to alleviate symptoms of psychosis and reduce the incidence of emesis. Chlorpromazine hydrochloride is typically administered orally or intramuscularly, and its dosage is carefully titrated to minimize the risk of adverse effects, such as extrapyramidal symptoms and sedation. As a first-generation antipsychotic, chlorpromazine hydrochloride has been largely superseded by newer agents with more favorable side effect profiles, although it remains a viable treatment option in certain clinical contexts.
